{"product_id":"abcam-ab219679","title":"Abcam, ab219679, Recombinant mouse CTLA4 protein (Fc Chimera Active)","description":"\u003cp\u003eSize: 200µg\u003cbr\u003e\nRecombinant mouse CTLA4 protein (Fc Chimera Active) is a Mouse Fragment protein, in the 36 to 162 aa range, expressed in HEK 293 cells, with \u0026gt;95%, \u0026lt; 1 EU\/µg endotoxin level, suitable for SDS-PAGE, FuncS.\u003cbr\u003e\nKey facts\u003cbr\u003e\nPurity:\u0026gt;95% SDS-PAGE,\u003cbr\u003e\nEndotoxin level:\u0026lt; 1 EU\/µg,\u003cbr\u003e\nExpression system:HEK 293 cells,\u003cbr\u003e\nTags:Fc tag C-Terminus,\u003cbr\u003e\nApplications:SDS-PAGE, FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nBiologically active:Yes,\u003cbr\u003e\nBiological activity:Measured by its binding ability in a functional ELISA. Immobilized recombinant mouse CD80 protein (Active) (ab220537) at 2 μg\/mL (100 μL\/well) can bind ab219679 with a linear range of 0.1-2 ng\/mL.,\u003cbr\u003e\nAccession:P09793,\u003cbr\u003e\nAnimal free:No,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nSpecies:Mouse,\u003cbr\u003e\nReconstitution:Reconstitute at 400 µg\/mL in water,\u003cbr\u003e\nStorage buffer:pH: 7.4Constituents: L-Arginine, Sodium chloride, 5% Trehalose, 0.75% Glycine, 0.61% Tris\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nThis product is stable after storage at:\u003cbr\u003e\n• -20°C to -70°C for 12 months in lyophilized state;\u003cbr\u003e\n• -70°C for 3 months under sterile conditions after reconstitution.\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nShipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nCTLA-4 also known as CD152 is an immune checkpoint receptor with a molecular weight of approximately 34 kDa. This protein is expressed on the surface of T-cells especially after activation and sometimes on regulatory T-cells (Tregs). CTLA-4 competes with CD28 for binding to the same ligands CD80 and CD86 on antigen-presenting cells. Unlike CD28 which stimulates T-cell activation CTLA-4 sends inhibitory signals to downregulate immune responses. By doing this CTLA-4 helps maintain immune system homeostasis and prevents autoimmune reactions.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nThe CTLA-4 protein functions as a critical regulator of the immune system. It interacts with CD80\/CD86 in a complex that effectively transmits inhibitory signals to T-cells. CTLA-4 controls the amplitude of the initial activation of T-cells ensuring that the body's immune responses are kept under control. In regulatory T-cells CTLA-4 engagement contributes to their immunosuppressive functions through which they maintain tolerance to self-antigens and prevent overactive immune reactions.\u003cbr\u003e\nPathways\u003cbr\u003e\nCTLA-4 involves itself in the adaptive immune response pathways specifically the regulation of T-cell activity. CTLA-4's interaction with CD80\/CD86 modulates pathways associated with TCR (T-cell receptor) signaling. When CTLA-4 binds its ligands it recruits phosphatases such as SHP-2 that dephosphorylate signaling proteins leading to the downregulation of T-cell interaction. This pathway interaction exemplifies how CTLA-4 acts in concert with proteins like CD28 to finely tune immune responses.\u003cbr\u003e\nCTLA-4 plays a role in autoimmune diseases and cancer. The dysregulation of CTLA-4 function can lead to autoimmune disorders where the immune system attacks the body's own tissue. In cancer tumor cells may manipulate CTLA-4 pathways to evade immune surveillance. Targeted therapies like anti-CTLA-4 antibodies such as ipilimumab have been developed to block CTLA-4 aiming to enhance the immune system’s ability to attack cancer cells. These treatments highlight the role of CTLA-4 in balancing immune activity and the potential to alter this balance for therapeutic benefit.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46843929362601,"sku":"ab219679","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/abcam-ab219679","provider":"Iright","version":"1.0","type":"link"}